NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (âKSFâ) are investigating the proposed sale of HilleVax, Inc. (NasdaqGS: HLVX) to XOMA Royalty Corporation (NasdaqGM: XOMA). Under the terms of the proposed transaction, shareholders of HilleVax will receive $1.95 in cash per share, plus one non-transferable contingent value right, representing the right to receive additional payments under cert
Related Questions
What are the potential regulatory or legal hurdles highlighted by the investigation that could delay or block the transaction?
How does the offer price compare to HLVX's recent trading range and its historical merger premiums?
How might the investigation by the former Louisiana Attorney General influence investor confidence and market perception of the deal?
Could the nonâtransferable contingent value right create a secondary market or impact liquidity for HLVX shares?
What are the financial health and synergy prospects of XOMA Royalty Corporation as the acquiring entity?
How does this proposed sale align with broader sector M&A trends and recent comparable transactions?
What is the likelihood that the contingent value right will be exercised and add value to shareholders?
Will the proposed transaction trigger any significant changes in trading volume or price volatility for HLVX and XOMA?
Will the deal affect any outstanding shareholder voting rights or trigger a proxy contest?
How might the market react if the investigation uncovers material deficiencies in the pricing or process?
How will the $1.95 cash consideration and contingent value right affect the current valuation of HLVX?
What are the tax implications for shareholders receiving the cash and contingent value rights?
What impact will the transaction have on HLVX's existing debt structure and cash flow forecasts?